A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation.

Transplantation research Pub Date : 2014-07-30 eCollection Date: 2014-01-01 DOI:10.1186/2047-1440-3-14

John C Mullen, Emily J Kuurstra, Antigone Oreopoulos, Michael J Bentley, Shaohua Wang

{"title":"A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation.","authors":"John C Mullen, Emily J Kuurstra, Antigone Oreopoulos, Michael J Bentley, Shaohua Wang","doi":"10.1186/2047-1440-3-14","DOIUrl":null,"url":null,"abstract":"Background: The purpose of this study was to test the efficacy and safety of daclizumab (DZM) versus anti-thymocyte globulin (ATG) as a component of induction therapy in heart transplant recipients.Methods: Thirty heart transplant patients were randomized to receive either ATG or DZM during induction therapy. Patients in the DZM group received an initial dose of 2 mg/kg intravenous (IV) at the time of transplant and 1 mg/kg IV on postoperative day 4.Discussion: Recipient, donor, and intraoperative variables did not differ significantly between groups. The cost of induction therapy, total drug cost, and hospital ward costs were significantly less for the DZM group. Average absolute lymphocyte and platelet counts were significantly higher in the DZM group. There were no significant differences in the incidence of rejection, infection, malignancy, or steroid-induced diabetes. One year survival was excellent in both groups (87%, P = 0.1). Daclizumab is a safe component of induction therapy in heart transplantation.","PeriodicalId":89864,"journal":{"name":"Transplantation research","volume":"3 ","pages":"14"},"PeriodicalIF":0.0000,"publicationDate":"2014-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/2047-1440-3-14","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/2047-1440-3-14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 10

Abstract

Background: The purpose of this study was to test the efficacy and safety of daclizumab (DZM) versus anti-thymocyte globulin (ATG) as a component of induction therapy in heart transplant recipients.

Methods: Thirty heart transplant patients were randomized to receive either ATG or DZM during induction therapy. Patients in the DZM group received an initial dose of 2 mg/kg intravenous (IV) at the time of transplant and 1 mg/kg IV on postoperative day 4.

Discussion: Recipient, donor, and intraoperative variables did not differ significantly between groups. The cost of induction therapy, total drug cost, and hospital ward costs were significantly less for the DZM group. Average absolute lymphocyte and platelet counts were significantly higher in the DZM group. There were no significant differences in the incidence of rejection, infection, malignancy, or steroid-induced diabetes. One year survival was excellent in both groups (87%, P = 0.1). Daclizumab is a safe component of induction therapy in heart transplantation.

Abstract Image

查看原文本刊更多论文

daclizumab与抗胸腺细胞球蛋白诱导心脏移植的随机对照试验。

背景:本研究的目的是测试daclizumab (DZM)与抗胸腺细胞球蛋白(ATG)作为心脏移植受体诱导治疗的一个组成部分的有效性和安全性。方法:30例心脏移植患者在诱导治疗期间随机接受ATG或DZM治疗。DZM组患者在移植时接受2 mg/kg静脉注射(IV)的初始剂量，术后第4天接受1 mg/kg静脉注射。讨论:两组间受体、供体和术中变量无显著差异。DZM组诱导治疗费用、总药物费用和住院费用均显著降低。DZM组平均绝对淋巴细胞和血小板计数明显升高。在排斥反应、感染、恶性肿瘤或激素性糖尿病的发生率方面没有显著差异。两组患者的1年生存率均极好(87%，P = 0.1)。Daclizumab是心脏移植诱导治疗的安全成分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation research

自引率

0.00%

发文量